AR047669A1 - Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion - Google Patents
Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacionInfo
- Publication number
- AR047669A1 AR047669A1 ARP050100512A ARP050100512A AR047669A1 AR 047669 A1 AR047669 A1 AR 047669A1 AR P050100512 A ARP050100512 A AR P050100512A AR P050100512 A ARP050100512 A AR P050100512A AR 047669 A1 AR047669 A1 AR 047669A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- alkyl
- different
- propyl
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una entidad seleccionada entre: un compuesto de xantina de formula (1), y un derivado fisiologicamente funcional del mismo, donde: R1 se selecciona entre: hidrogeno y alquilo C1-4 que puede estar opcionalmente sustituido con uno o más grupos seleccionados entre CN y CF3; R2 se selecciona entre: alquilo C3-10 no sustituido, alquilo C1-10 sustituido con uno o más grupos seleccionados entre fluor y CN, alquenilo C5, alquenilo C4 no ramificado, y alquilo C1-4 sustituido con cicloalquilo; y R3 se selecciona entre halogeno y CN; con las condiciones de que: i) cuando R3 representa Cl, y R1 representa etilo, R2 es distinto de propilo; ii) cuando R3 representa Br, y R1 representa propilo, R2 es distinto de propilo; iii) cuando R3 representa Cl o Br, y R1 representa butilo, R2 es distinto de butilo; y iv) cuando R1 representa alquilo C1-4, CH2CN o (CH2)3CF3, R2 es distinto de alquilo ramificado. Uso de dicha entidad para la fabricacion de un medicamento para el tratamiento de la dislipidemia diabética, dislipidemia, mixta, insuficiencia cardiaca, hipercolesteremia, enfermedad cardiovascular, incluyendo aterosclerosis, arteriosclerosis e hipertrigliceridemia, diabetes mellitus de tipo II, diabetes de tipo I, resistencia a insulina, hiperlipidemia, anorexia nerviosa, obesidad, enfermedad de las arterias coronarias, trombosis, angina, insuficiencia renal cronica o apoplejía, afecciones en las que una infraactivacion del receptor HM74A contribuye a la mismas, o en la que la activacion del receptor será beneficiosa. Formulacion farmacéutica que comprende el compuesto y uno o más diluyentes, excipientes o vehículos fisiologicamente aceptables y combinacion para la administracion conjunta o separada, secuencial o simultánea en formulaciones farmacéuticas separadas o combinadas, que comprende el compuesto junto con otro agente terapéuticamente activo. Método para la preparacion del compuesto de la formula (1).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403282A GB0403282D0 (en) | 2004-02-14 | 2004-02-14 | Chemical compounds |
| GB0423562A GB0423562D0 (en) | 2004-10-22 | 2004-10-22 | Novel compounds |
| GB0428375A GB0428375D0 (en) | 2004-12-24 | 2004-12-24 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047669A1 true AR047669A1 (es) | 2006-02-01 |
Family
ID=34864831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100512A AR047669A1 (es) | 2004-02-14 | 2005-02-14 | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US7713982B2 (es) |
| EP (1) | EP1781657B1 (es) |
| JP (2) | JP5001012B2 (es) |
| KR (1) | KR101100601B1 (es) |
| CN (2) | CN101103030B (es) |
| AR (1) | AR047669A1 (es) |
| AU (1) | AU2005212816C1 (es) |
| BR (1) | BRPI0507604A (es) |
| CA (1) | CA2556073C (es) |
| CY (1) | CY1114022T1 (es) |
| DK (1) | DK1781657T3 (es) |
| ES (1) | ES2406732T3 (es) |
| HK (1) | HK1104530A1 (es) |
| HR (1) | HRP20130406T1 (es) |
| IL (1) | IL177051A (es) |
| MA (1) | MA28357A1 (es) |
| MY (1) | MY148937A (es) |
| NO (1) | NO337281B1 (es) |
| NZ (1) | NZ548496A (es) |
| PE (1) | PE20060317A1 (es) |
| PL (1) | PL1781657T3 (es) |
| PT (1) | PT1781657E (es) |
| SG (1) | SG157242A1 (es) |
| SI (1) | SI1781657T1 (es) |
| TW (1) | TWI350289B (es) |
| WO (1) | WO2005077950A2 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50381B (sr) * | 1999-11-12 | 2009-11-10 | Biogen Idec Ma Inc., | Policikloalkilpurini kao adenozin receptor antagonisti |
| AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| PL1781657T3 (pl) * | 2004-02-14 | 2013-08-30 | Glaxosmithkline Ip Dev Ltd | Leki o aktywności wobec receptora HM74A |
| CA2589483C (en) | 2004-12-03 | 2013-10-29 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AU2006247695B2 (en) | 2005-05-17 | 2012-08-09 | Merck Sharp & Dohme Corp. | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
| BRPI0611784A2 (pt) | 2005-06-14 | 2010-09-28 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e utilização desses compostos |
| EP1901731B1 (en) | 2005-06-28 | 2011-03-02 | Merck Sharp & Dohme Corp. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| EP2272848B1 (en) * | 2005-08-10 | 2012-12-26 | Glaxosmithkline LLC | Xanthine derivatives as selective HM74A agonists |
| CA2637717A1 (en) * | 2006-01-20 | 2007-08-02 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia |
| CN101448836B (zh) | 2006-05-23 | 2011-12-14 | 霍夫曼-拉罗奇有限公司 | 吡啶并嘧啶酮衍生物 |
| TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
| ATE486874T1 (de) | 2006-06-23 | 2010-11-15 | Incyte Corp | Purinonderivate als hm74a-agonisten |
| BRPI0713619A2 (pt) | 2006-06-23 | 2013-01-15 | Incyte Corp | composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto. |
| KR101115891B1 (ko) * | 2007-03-23 | 2012-02-13 | 에프. 호프만-라 로슈 아게 | 아자-피리도피리미딘온 유도체 |
| KR101743783B1 (ko) * | 2008-12-08 | 2017-06-05 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| CN102276610B (zh) * | 2011-05-04 | 2013-01-09 | 北京工业大学 | N7-鸟嘌呤烷化物的制备方法 |
| CN103360394B (zh) * | 2013-07-29 | 2015-07-22 | 上海万巷制药有限公司 | 8-氯茶碱的制备方法 |
| SI3251675T1 (sl) * | 2015-01-30 | 2021-08-31 | Shanton Pharma Pte. Ltd. | Preprečevanje ali zdravljenje sečnokislinske ali protinske bolezni |
| CN104892610B (zh) * | 2015-05-27 | 2016-08-24 | 福建师范大学 | 一种8-酯基咖啡因衍生物的制备方法 |
| CN105622610A (zh) * | 2016-03-28 | 2016-06-01 | 浙江诚意药业股份有限公司 | 一种黄嘌呤化合物的制备方法 |
| WO2018019911A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Therapeutic combinations to treat red blood cell disorders |
| CN106632061B (zh) * | 2016-11-23 | 2020-07-24 | 上海皓元医药股份有限公司 | 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法 |
| AR113206A1 (es) | 2017-01-10 | 2020-02-19 | Bayer Cropscience Ag | Derivados heterocíclicos como pesticidas |
| CN114727983A (zh) * | 2019-09-25 | 2022-07-08 | 金翅雀生物公司 | 黄嘌呤cb1抑制剂 |
| CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
| CN113262882B (zh) * | 2021-07-21 | 2021-09-17 | 北京矿冶研究总院 | 阳离子捕收剂、制备方法及在磷矿反浮选中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2797220A (en) * | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
| US4847377A (en) * | 1985-05-13 | 1989-07-11 | Schering Corporation | Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones |
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| NZ240644A (en) * | 1990-11-21 | 1994-08-26 | Smithkline Beecham Corp | Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf) |
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| DK0584347T3 (da) | 1992-03-04 | 2003-02-24 | Cell Therapeutics Inc | Enantiomere hydroxylerede xanthinforbindelser |
| US5804584A (en) | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| US6693105B1 (en) * | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US6469017B1 (en) * | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| WO1994024133A1 (en) | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
| US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
| US6103730A (en) * | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US5807861A (en) * | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| CA2369981A1 (en) | 1999-04-09 | 2000-10-19 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
| US20030207901A1 (en) * | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| MXPA02002262A (es) * | 1999-08-31 | 2002-09-30 | Univ Vanderbilt | Antagonistas selectivos de los receptores adenosina a2b. |
| WO2002008237A2 (en) * | 2000-07-21 | 2002-01-31 | Lyles Mark B | Materials and methods for binding nucleic acids to surfaces |
| FR2812482B1 (fr) * | 2000-07-28 | 2003-01-24 | Inside Technologies | Dispositif electronique portable comprenant plusieurs circuits integres sans contact |
| JP2004512278A (ja) * | 2000-09-19 | 2004-04-22 | ノビムーヌ ソシエテ アノニム | 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤） |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| AU2002234640B8 (en) * | 2001-02-24 | 2009-11-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivative, production and use thereof as a medicament |
| AU2002242910A1 (en) * | 2001-04-11 | 2002-10-28 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
| PL1781657T3 (pl) | 2004-02-14 | 2013-08-30 | Glaxosmithkline Ip Dev Ltd | Leki o aktywności wobec receptora HM74A |
| US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| WO2006045564A1 (en) | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| EP2272848B1 (en) * | 2005-08-10 | 2012-12-26 | Glaxosmithkline LLC | Xanthine derivatives as selective HM74A agonists |
| EP1939197A1 (en) * | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| KR101743783B1 (ko) * | 2008-12-08 | 2017-06-05 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| US20110065676A1 (en) * | 2009-06-24 | 2011-03-17 | Schering Corporation | Combination therapies comprising par1 antagonists with nar agonists |
-
2005
- 2005-02-10 PL PL05707363T patent/PL1781657T3/pl unknown
- 2005-02-10 CN CN2005800114336A patent/CN101103030B/zh not_active Expired - Fee Related
- 2005-02-10 EP EP05707363A patent/EP1781657B1/en active Active
- 2005-02-10 SG SG200803771-5A patent/SG157242A1/en unknown
- 2005-02-10 SI SI200531730T patent/SI1781657T1/sl unknown
- 2005-02-10 ES ES05707363T patent/ES2406732T3/es active Active
- 2005-02-10 AU AU2005212816A patent/AU2005212816C1/en not_active Ceased
- 2005-02-10 BR BRPI0507604-8A patent/BRPI0507604A/pt not_active Application Discontinuation
- 2005-02-10 KR KR1020067016277A patent/KR101100601B1/ko active IP Right Grant
- 2005-02-10 CA CA2556073A patent/CA2556073C/en not_active Expired - Fee Related
- 2005-02-10 US US10/589,474 patent/US7713982B2/en not_active Expired - Fee Related
- 2005-02-10 CN CN2010102007350A patent/CN101863888B/zh not_active Expired - Fee Related
- 2005-02-10 JP JP2006552565A patent/JP5001012B2/ja not_active Expired - Fee Related
- 2005-02-10 WO PCT/EP2005/001449 patent/WO2005077950A2/en active Application Filing
- 2005-02-10 NZ NZ548496A patent/NZ548496A/en not_active IP Right Cessation
- 2005-02-10 PT PT57073637T patent/PT1781657E/pt unknown
- 2005-02-10 DK DK05707363.7T patent/DK1781657T3/da active
- 2005-02-11 PE PE2005000170A patent/PE20060317A1/es not_active Application Discontinuation
- 2005-02-14 TW TW094104133A patent/TWI350289B/zh not_active IP Right Cessation
- 2005-02-14 MY MYPI20050527A patent/MY148937A/en unknown
- 2005-02-14 AR ARP050100512A patent/AR047669A1/es not_active Application Discontinuation
-
2006
- 2006-07-24 IL IL177051A patent/IL177051A/en not_active IP Right Cessation
- 2006-08-11 MA MA29262A patent/MA28357A1/fr unknown
- 2006-09-13 NO NO20064151A patent/NO337281B1/no not_active IP Right Cessation
-
2007
- 2007-09-04 HK HK07109621.1A patent/HK1104530A1/xx not_active IP Right Cessation
-
2008
- 2008-02-12 JP JP2008030344A patent/JP5020848B2/ja not_active Expired - Fee Related
-
2009
- 2009-09-02 US US12/552,649 patent/US8394808B2/en not_active Expired - Fee Related
-
2010
- 2010-03-04 US US12/717,349 patent/US8268839B2/en not_active Expired - Fee Related
-
2013
- 2013-02-06 US US13/760,423 patent/US20130150383A1/en not_active Abandoned
- 2013-05-08 HR HRP20130406TT patent/HRP20130406T1/hr unknown
- 2013-05-29 CY CY20131100430T patent/CY1114022T1/el unknown
-
2014
- 2014-11-21 US US14/549,721 patent/US20150080418A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
| JP2007522176A5 (es) | ||
| JP2020045362A5 (es) | ||
| Ahrén et al. | Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans | |
| HRP20100725T1 (hr) | Derivati ksantina kao selektivni agonisti hm74a | |
| Fowler | Diabetes treatment, part 2: oral agents for glycemic management. | |
| ECSP045103A (es) | Compuestos heterociclicos y metodos de uso | |
| RU2006131597A (ru) | Ингибиторы dпп-iv | |
| CO6150170A2 (es) | Derivados de 1-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| PH12016502294A1 (en) | Novel fatty acids and their use in conjugation to biomolecules | |
| JP2019531320A5 (es) | ||
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| CA2851690A1 (en) | Treatment protocol of diabetes type 2 | |
| JP2015503539A5 (es) | ||
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| CR8047A (es) | Procedimiento de tratamiento de la arterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas | |
| RU2003127750A (ru) | 4-фтор-n-индан-2-илбензамид и его применение в качестве фармацевтического агента | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| NO20056056L (no) | N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer | |
| BRPI0516446A (pt) | combinação de compostos orgánicos | |
| JP2007502263A5 (es) | ||
| MX367769B (es) | Nuevo derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico, metodo de preparacion del mismo y composicion farmaceutica para la prevencion y tratamiento de la enfermedad metabolica que incluye el mismo como ingrediente activo. | |
| BR112022013009A2 (pt) | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina | |
| AR117640A1 (es) | Compuestos de 2,6-diaminopiridina como inhibidores de khk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |